Background: Population-based serologic studies are a vital tool for understanding the epidemiology of influenza and other respiratory viruses, including the early assessment of the transmissibility and severity of the 2009 influenza pandemic, and Middle East respiratory syndrome coronavirus. However, interpretation of the results of serologic studies has been hampered by the diversity of approaches and the lack of standardized methods and reporting.
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antibodies and may be at higher risk of infection with pathogens for which the primary determinant of protection is humoral immunity, for and Winnipeg. 5, 6 However, inconsistencies in the reporting and standardization of both survey and laboratory methods have limited the comparability of results of 2009 H1N1 pandemic influenza seroepidemiologic studies. 7, 8 Debate has also arisen around the interpretation of seroepidemiologic studies of avian influenza A virus (AIV) infections of humans, given uncertainties about assay performance and antibody kinetics in exposed and unexposed populations. [9] [10] [11] In addition, new immunoassays and modifications of well-established assays are increasingly being used for the detection of influenza virus strainspecific antibodies. [12] [13] [14] [15] [16] [17] [18] These issues led to the formation in 2010 of the Consortium for the Standardization of Influenza Seroepidemiology (CONSISE). 19 CONSISE is comprised of international scientists experienced in conducting seroepidemiologic studies of influenza and other emerging respiratory viruses; two working groups on epidemiology and laboratory matters were formed to provide tools to help standardize protocols and laboratory methods used (see https://consise.tghn.org/ about/working-group-projects/). The overarching goal of CONSISE is to improve the quality of data arising from influenza seroepidemiologic studies, harmonize methods used in such studies, and thereby provide better evidence for policy makers that guides rational implementation of intervention and control measures. 19 Guidelines for the reporting of the design, conduct, and results of research have been an effective tool for improving the quality and interpretability of published data. Examples include the Consolidated
Standards of Reporting Trials (CONSORT) and the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE). 20, 21 These guidelines have become, in some instances, widely accepted standards for reporting of research studies, and the expectation that publications should meet these standards has helped to improve the design and conduct of studies. CONSISE has prepared the following statement, Reporting Of Sero-Epidemiologic Studies for Influenza (ROSES-I), which distills the experience of the working groups into a set of recommendations on the optimal reporting of influenza seroepidemiologic studies.
| Objective
The aim of the CONSISE ROSES-I statement was to improve the quality and transparency of reporting of seasonal, avian, and pandemic influenza seroepidemiologic studies in order for the validity and generalizability of the results to be better assessed. This statement also aims to improve the design and conduct of influenza seroepidemiologic studies by proposing reporting standards that investigators should consider when designing studies. CONSISE has developed a number of protocols as guides to the design and implementation of seroepidemiologic studies, and these protocols (available at https://consise.
tghn.org/articles/available-consise-influenza-protocols/) are a valuable resource that should be consulted in addition to the ROSES-I statement ( Table 1 ).
The components of the ROSES-I statement can be used as a checklist to help guide what key information should be included in the results of published seroepidemiologic studies, and can also serve as a guide to the items that need to be considered during study design and implementation. As with other reporting guidelines, this statement is not intended as a required framework that must be followed in content and format. It is also not designed as an instrument for assessing study quality, for which other instruments exist 22, 23 .
| METHODS
The need for the ROSES-I statement was agreed at the 4th 
| RESULTS

| ROSES-I standards
| Title and abstract
To facilitate the clear identification of studies that quantitatively measure antibodies concentration in members of a defined population in order to make inferences about exposure of that population to emerging respiratory viruses, transmission, and severity, one of the terms "seroepidemiologic," "seroepidemiology," "seroprevalence,"
or "seroincidence" should be used in the title and/or abstract of the study, and the MeSH term "Seroepidemiologic Studies" should be used as a keyword [ROSES-I 1.1] ( Table 2 ).
| Introduction
The serum specimens provides estimates of the cumulative incidence of virus infection (or incidence proportion). Serial cross-sectional or prospective longitudinal cohort studies can be used to estimate cumulative incidence of virus infection. 4 Serology can also be used in studies The term "seroepidemiologic," "seroepidemiology," "seroprevalence," or "seroincidence" should be applied to the study in the title or abstract, and the medical subject heading "Seroepidemiologic Studies" be used when the report is of a population-based serological survey 
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Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why ROSES-I 11.1: Describe the serological assay's limit of detection and how this limit is defined or calculated. Describe how samples with a result below or on the borderline of the limit were handled in the analysis ROSES-I 11.2: Describe and justify the titer or other result used to define "seropositivity," or the antibody titer change or change in other assay result used to define "seroconversion." Avoid the term "seroconversion" unless referring to change from undetectable to detectable antibody level.
Otherwise report the fold-rise in titer. Avoid the term "infection" but report "seroprevalence at a titer of …."
ROSES-I 11. 
| Epidemiological methods
Study design and setting
A number of different seroepidemiologic study designs can be used to estimate various measures of virus infection risk, and different designs have different strengths and weaknesses depending on the objectives of the investigation ( Table 1 ). The methods section should begin by describing the study design, the study population, sampling procedures (e.g., random or convenience), the source of serum or plasma that was analyzed (e.g., frozen stored vs recently collected and tested), the rationale for choosing the study design, and the gen- 
Participants
For studies where close contacts of confirmed influenza cases (e.g., household contacts of confirmed cases; Table 1 : household transmission studies) are monitored for seroconversion in order to estimate the incidence of secondary infections, in addition to the STROBE criteria for reporting study subject details, the method and criteria for identifying index case patients should be reported because the probability of onward transmission may vary according to the characteristics of the index case patients (Table 2) 
Variables, data sources, and bias
Age is an important determinant of serologic responses to virus infection, and therefore, it is critical that the median and range of the age of participants, overall and by subgroup (study subjects and control population; the control group should have a similar median age and age range to the study group.), should be reported (ROSES-I 7. 
Study subjects and sample size
In order to permit the generalizability of the study results, it is preferable that the study population be as close as possible to the general population under study. However, this is not always feasible, and for example, many serologic studies detecting antibodies to A(H1N1) pdm09 virus infection were conducted using residual sera from blood donors 4,28 or hospitalized patients, 29 who may not be representative of the broader populations in those locations. The potential to introduce selection bias into the study should be addressed in the discussion. Any method used to infer cumulative incidence of infection among the population based on results from the study sample, for example, weighting or standardization, should be reported in sufficient detail to permit reproducibility (ROSES-I 16.2).
In addition, the confidence in the results and conclusions of any seroepidemiologic study depends, among other things, on whether the planned study sample size was sufficient to provide estimates of prevalence or incidence of infection with sufficient precision and certainty. 30 To assess whether the planned sample size was adequate, the assumed baseline prevalence of given antibody titers or the baseline cumulative incidence of a given change in antibody titer should be reported [ROSES-I 10.1]. Differences between the planned and actual sample size should also be reported, and any differences explained.
Quantitative variables
For seroepidemiologic studies, it is particularly important that full How these titers are analyzed and interpreted can affect the results, especially if they constitute a large proportion of the results. A common convention, which is acceptable, is to consider a result below the limit of detection as a serial step below that limit; that is, if the starting antibody dilution is 10, then a value of <10 can be reported as a five for the purposes of data analysis rather than a zero or a "not detected." Similarly, antibody titer thresholds to define a seropositive result are critically important yet are, in some studies, fairly arbitrary.
Thresholds that are designed with high specificity for diagnostic purposes in the cases of clinical illness may not provide reliable estimates of virus infection rates at the population level, if specificity has been optimized at the expense of sensitivity. 
Statistical methods and presentation of results
In cross-sectional studies, seroprevalence can be estimated by the proportion of specimens with antibody titers at or above a specific threshold, with 95% confidence intervals typically obtained using the binomial formula or the normal approximation to the binomial. If a number of additional assumptions are met, including that seroprevalence before an epidemic is very low, and almost all infected individuals have rises in convalescent antibody titers above the chosen threshold, the post-epidemic seroprevalence can provide an approximate estimate of the cumulative incidence of infection. 34 Note that seroprevalence is a proportion and not a rate.
In studies with paired sera, the cumulative incidence of virus infection can be estimated by the proportion of persons with a rise in antibody titer, traditionally a fourfold or greater rise. 31 In most studies, 95% confidence intervals are typically estimated using the binomial formula or the normal approximation to the binomial, implicitly assuming that each person can experience no more than one virus infection during the period considered. It is noteworthy to point out also that cumulative incidence of virus infection is sometimes referred to as an "attack rate," although a proportion of infections may be asymptomatic (and therefore not "attacks"), and the quantity measured is a proportion and not a rate. The term "cumulative incidence of infection" should therefore be preferred to "attack rate" in the context of serological studies.
In either case, the methods used to account for the probability of seropositivity or seroconversion if infected, and any method used to account for decay in antibody titer over time, should be reported (ROSES-I 12.2). To increase transparency of cumulative incidence of infection estimates, it is often helpful to report unadjusted estimates of the distribution of antibody titers by age group (ROSES-I 16.1).
In some studies, particularly those with more complex designs in terms of timing of serologic measurements, improved estimates of the seroprevalence at a certain point in time, or the cumulative incidence of infection over a specified time period, may be obtained by fitting observed data to a mechanistic model of transmission dynamics. 4, 35 This can account for non-independence in the data (ROSES-I 12.1).
| Laboratory methods
Sample type and handling
Although serum samples are more commonly used for serologic studies, convenience sampling may only enable access to plasma. The use of anticoagulants to separate plasma has been shown to reduce the antibody titer to some influenza viruses. 36 Thus, defining the sample type and anticoagulant, if used, is necessary (ROSES-I 12a.1). The storage conditions, duration, and subsequent treatment of samples (e.g., temperature and the number of freeze/thaw cycles) are important to report, if known, as repeated freeze/thaw cycles may also reduce the antibody titer (ROSES-I 12a.2).
Serologic assays
Where possible, standard serologic assays [e.g., hemagglutination inhibition (HAI) assay to detect HAI antibodies or microneutralization (MN) assay to detect neutralizing antibodies for influenza viruses] should be used.
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All specimen preparation and assay protocols should be provided, either referenced to a published protocol, with any changes specified, or as detailed methodology for novel serologic assays (ROSES-I 12a. and the criteria for positivity also need to be described in the same details as above (ROSES-I 12a.13). 38, 39 Inclusion of available international standards 40, 41 facilitates the comparability of serological data.
Inclusion of the actual titers obtained from the international standards and indication whether the data are reported as raw values or international standard-adjusted values should therefore be described (ROSES-I 12a.14).
Results
Unadjusted estimates of titers by age group should be reported (ROSES-I 16.1) and where the results from the study sample have been standardized to a general or target population, the method of standardization should be reported (ROSES-I 16.2).
Discussion
Different seroepidemiologic study designs have different strengths and weaknesses, which have been reviewed and summarized by the CONSISE group (Table 1) . The limitations and strengths of the study design being reported should be covered in the discussion (ROSES-I 19.1). 
| CONCLUSIONS
The direct comparability of influenza seroepidemiologic studies is currently limited by a lack of standardization across such studies. 8 The ROSES-I statement aims to improve the quality and transparency of the reporting of such studies so that such studies can be better assessed and understood. Here, we have outlined which methodological details-study design, study population, epidemiologic data collection, specimen collection and handling methods, laboratory methods, justification of criteria for seropositivity, reporting of results, limitations and biases, and interpretation-should be included when reporting the findings of seroepidemiologic studies.
Our aim is for the ROSES-I, like other standards of reporting (e.g.,
CONSORT, STROBE), to be developed and accepted as the standard for reporting of influenza seroepidemiologic studies. When novel influenza A viruses emerge, a rapid and robust evaluation of the implications of seroepidemiologic studies is critical in order to fully assess the population health risks and the need for mitigation measures. Without the ROSES-I-recommended information for reporting, our ability to interpret seroepidemiologic studies of novel influenza A viruses will be limited.
This is the first version of the ROSES-I checklist, and we hope this will be refined with use and feedback. The approach used by CONSISE for influenza seroepidemiologic studies and the items outlined in this statement are likely to be applicable or adaptable to other emerging respiratory viruses, such as Middle East respiratory syndrome coronavirus (MERS-CoV); however for simplicity, the ROSES-I statement described here is focused on influenza viruses. For this reason, we have entitled this statement ROSES-I, to allow for extension of the acronym ROSES to other such pathogens.
